The bactericidal activity of two new 4-quinolones, DU-6859a and DV-775 la, was investigated against strains of Escherichia coli, Staphylococcus aureus, S. epidermidis, Streptococcus pneumoniae and Enterococcus faecalis. DU-6859a and DV-775 1 a were more bactericidal than any 4-quinolone tested previously. Furthermore, DU-6859a was unique among 4-quinolones in being able to kill Ent. faecalis after incubation for only 3 h in nutrient broth. The bactericidal mechanisms of DV-755 1 a were similar to those of other 4-quinolones, but, uniquely, DU-6859a possessed additional bactericidal mechanisms against both Str. pneumoniae and Ent. faecalis. This may explain the unusually potent bactericidal activity of this agent against these species. These results show that DU-6859a is a unique extendedspectrum 4-quinolone, which should prove to be superior to established 4-quinolones.
Introduction
Preliminary studies have suggested that DU-6859a and DV-7751a may be significantly more active than currently available 4-quinolones against a wide range of bacteria.', To investigate this claim further, their bactericidal activity was studied against strains of Escherichia coli, Staphylococcus aureus, S. epidermidis, Streptococcus pneumoniae and Enterococcus faecalis.
The bactericidal activity of 4-quinolones has been described with respect to three mechanisms of action, termed A, B and C. Mechanism A requires the bacteria to be undergoing multiplication and protein or RNA synthesis. It occurs with all 4-quinolones, except when high concentrations are used against Pseudomonas ae~uginosa,~ and is the sole bactericidal mechanism of older 4-quinolones, such as nalidixic and oxolinic acids.* Mechanism B is an additional mechanism of several modern 4-quinolones including ofloxacin, ciprofl~xacin,~ lomefloxacin,6 levofloxacin,' fleroxacin, pefloxacin,* PD13 16289 and sparfloxacin.lO Unlike mechanism A, mechanism B allows bactericidal activity against non-dividing bacteria and does not require active protein or RNA ~ynthesis.~ A related bactericidal mechanism, termed B,, has been identified with clinafloxacin (PD127,391.)" Although it does not require active protein or RNA synthesis, mechanism B,, is nevertheless lost against non-dividing bacteria.ll Mechanism C, which has so far been found only with norfloxacin12 and enoxacin,6 does not require bacterial multiplication, but does need active protein and RNA synthesis.
Possession of additional mechanisms against one bacterial species does not guarantee their occurrence against others. For example, ciprofloxacin has mechanism B against E. C O Z~,~ but possesses only mechanism A against staphylococ~i.~~ Ofloxacin, on the other hand, exerts mechanism B against both E. coli and staphyloc~cci,~. l3 as does levofloxacin.' All 4quinolones tested so far possess only bactericidal mechanism A against Str. pneumoniael* and Ent. faecalis,15 and these species represent a considerable weakness in the bactericidal spectrum of 4-quinolones. This is especially pertinent for Ent. faecalis, for which the rate of bactericidal activity of 4-quinolones is slower than for other gram-positive b a~t e r i a .~~ l 5 This study aimed to characterise the bactericidal mechanisms of DU-6859a and DV-7751a and to determine if they had any advantage over earlier agents against pneumococci and enterococci.
Materials and methods
Bacterial strains E. coli KL16,16 S . epidermidis SK360,13 S. aureus E3T,17 Str. pneumoniae C3LN41s and Ent. faecalis ATCC 1943315 were used. These species and strains were chosen because of their previous use in determining the bactericidal activity and mechanisms of action of other 4-quinolones.
An tibacterial agents
DU-6859a and DV-775 1 a (Daiichi Pharmaceutical Co., Japan) were initially dissolved in 0.1 M NaOH at 10 mg/ml and immediately diluted with sterile distilled water. Chloramphenicol (Parke-Davis, Pontypool, Gwent) was prepared initially in methanol and diluted further in sterile distilled water.
Determination of the bactericidal activities of DU-68.59~ and DV-7751a
Ten ml of Nutrient Broth No. 2 (Unipath Basingstoke, Hants) was inoculated with bacteria and then incubated overnight at 37°C to provide organisms for study. For Str. pneumoniae cultures, the nutrient broth was supplemented with laked horse blood (Unipath) 7 YO.
To study bactericidal activity, sterile doublestrength nutrient broth first was dispensed in 5-ml volumes in sterile 1 oz bottles. The aqueous 4quinolone and sterile distilled water were then added to give a final volume of 9.8 ml, and a drug concentration between 0.01 5 and 90 mg/l. When Str. pneumoniae was tested, laked horse blood was added to a final concentration of 7%. When required, aqueous chloramphenicol was also added to a final concentration of 20 mg/l or 2.5 mg/l for Str. pneumoniae. These concentrations of chloramphenicol were bacteriostatic (data not shown). The bottles were then warmed for at least 15 min in a waterbath at 37"C, after which 0.2 ml of overnight culture, containing c. 2.5 x lo8 cfu/ml, was added. Viable counts at time zero thus were c. 5 x lo6 cfu/ml.
In some experiments PBS (NaC1 0.9% in 0.025 M sodium phosphate buffer, pH 7.4), replaced nutrient broth. In these cases the overnight cultures used were harvested by centrifugation at 4000 rpm for 15 min, washed, and then resuspended in 10 ml of sterile PBS to prevent nutrient carry-over. To prevent autolysis of Str. pneumoniae, horse serum (Unipath) 7% was added when this organism was studied.
All incubations were for 3 h at 37"C, except that Ent. faecaZis cultures also were incubated for 6 and 24 h. Experiments were stopped by adding 10 ml of sterile ice-cold nutrient broth, after which the cells were harvested by centrifugation at 4000 rpm for 15 min, then resuspended in 10 ml of sterile nutrient broth at room temperature to prevent drug carry-over. Viable counts were determined by serial dilution in sterile nutrient broth at room temperature, and 0. 1-ml amounts of the dilutions were spread on nutrient agar, supplemented with laked horse blood 7% for Str. pneumoniae. Owing to the strong bactericidal activity of DU-6859a against E. coli, a total volume of 1 ml was spread in three samples of 0.3 ml and one of 0.1 ml when this agent was tested at concentrations between 0.5 and 3 mg/l. All plates were incubated for 2 days at 37°C before the colonies were counted.
Results
A biphasic dose response occurred with DU-6859a against E. coli, with an optimum bactericidal concentration (OBC) of 0.9 mg/l ( fig. 1 ). Most killing occurred in normal nutrient broth culture, but considerable killing was still achieved when a bacteriostatic concentration of the protein synthesis inhibitor chloramphenicol was added or when the bacteria were resuspended in PBS prior to exposure to the quinolone. Similar behaviour was seen for DV-775 1 a against E. coZi and for both DU-6859a or DV-7751a against S. aureus or S. epidermidis (not shown).
The proportions of E. coZi, S. aureus, S. epidermidis and Str. pneumoniae cells that survived exposure to DU-6859a or DV-7751a at OBC are shown in the table. Both drugs had OBCs of 0-9 mg/l for E. coli, but DV-7751a had lower OBCs than DU-6859a for staphylococci. The extent of killing by either DU-6859a or DV-7751a at OBC in nutrient broth was greater than with any 4-quinolone studied previously. In nutrient broth, DU-6859a was 58 times more bactericidal than DV-7751a against E. coli and 19 times more so against S. epidermidis, but both 4-quinolones had approximately equal bactericidal activity at OBC against S. aureus. However, DU-6859a was more bactericidal than DV-775 l a against all three of these species in nutrient broth containing chloramphenicol, or in PBS.
DV pneumoniae in blood broth and was less so when a bacteriostatic concentration of chloramphenicol was added, or when tested in PBS plus horse serum 7 %. Nevertheless, some killing did occur under these latter conditions ( fig. 2a ). In contrast, DU-6859a was equally potent against pneumococci in blood broth whether or not chloramphenicol was added (fig. 2b) , and was only slightly less bactericidal in PBS plus horse serum. This strong bactericidal activity of DU-6859a against nondividing Str. pneumoniae is unique among 4-quinolone antibacterial agents.
Weak bactericidal activity was seen for DV-7751a against Ent. faecalis after incubation for 3 h in nutrient broth at 37"C, but more significant killing was seen only after incubation for 6 or 24 h ( fig. 3a) . By contrast, DU-6859a had good bactericidal activity against this organism within 3 h in nutrient broth at 37°C (fig. 3b ), although still more killing was observed after 6 or 24 h. This rapid bactericidal activity of DU-6859a against Ent. faecalis is also unique among 4-quinolones. When bactericidal activity was tested against non-dividing enterococci in PBS, no significant killing occurred with DV-775 la up to 90 mg/L, even after 24 h ( fig. 4a ), nor, during exposure periods shorter thafi 24 h, in nutrient broth containing chloramphenicol. DU-6859a did not kill Ent. fueculis in PBS even after 24 h ( fig. 4b) ; but, unlike with DV-7751a, bactericidal activity was seen in nutrient broth containing chloramphenicol, with 10, 1 and 0.01 % survivors remaining after incubation for 3, 6 and 24 h, respectively. These results show that DU-6859a, unlike DV-775 la, possessed another bactericidal mechanism, in addition to mechanism A, against Ent. faecalis, and may explain the compound's rapid bactericidal rate against this species. 
Discussion
DV-7751a had very similar OBCs against E. coli, S. aureus and S. epidermidis. This is unusual among 4quinolones, and has only been seen previously with sparfIoxacin.lo DU-6859a, on the other hand, was more like other 4-quinolones in that its OBC for E. coli was about three-fold lower than for either staphylococcal species. However, comparison of OBCs alone may not allow a fair assessment of DV-7751a and DU-6859a because both drugs were extremely bactericidal at even lower concentrations. This was especially marked for DU-6859a against E. coli, where a modification of the usual viable counting method
The bactericidal activity and mechanisms of many 4-quinolones have been studied p r e v i o u~l y .~-~~ In this study, the bactericidal activities and mechanisms of action of two new 4-quinolones, DU-6859a and DV-775 la, were investigated against the same test strains used in these earlier studies. DV-7751a and DU-6859a, like many other 4-quinolones, displayed another bactericidal mechanism, in addition to mechanism A, against E. coli, S. aureus and S. epidermidis. This appeared to be mechanism B, because both drugs could kill bacteria in the absence of active protein or was necessary to enumerate the few survivors. RNA synthesis and when the bacteria were not OBCs of both new quinolones against Str. multiplying.
pneumoniae were considerably lower than those of other 4-quinolones." Moreover, both DV-775 la and DU-6859a were able to kill Str. pneumoniae in the absence of active protein or RNA synthesis, or when the bacteria were not multiplying. indicating the presence of mechanism B. All 4-quinolones previously tested showed only mechanism A against this species.14 The occurrence of mechanism B may explain the greater bactericidal activity of these drugs for pneumococci and may be extremely useful in the treatment of infections, where the bacteria may not be dividing. Mechanism B was particularly strong with DU-6859a-where essentially the same extent of killing was seen against Str. pneumoniae in blood broth whether or not a bacteriostatic concentration of chloramphenicol was added. Possession of such a powerful mechanism B suggests that DU-6859a might be used in combination with those antibacterial agents that inhibit bacterial protein synthesis, whereas the bactericidal activity of other 4-quinolones may be seriously impaired by inhibitors of protein synthesis, as has been shown with levoflo~acin.'~ Such combination therapy might be desirable to prevent the development of bacteria 1 resistance. Previous 4-quinolones have had very slow rates of bactericidal activity against Ent. faecalisg. l 5 although, contrary to a recent claim,2o they are not merely bacteriostatic against these organisms. In this study a slow rate of bactericidal activity was seen with DV-775 la, although reasonable killing occurred after exposure for 6 h, whereas other 4-quinolones require
